161 related articles for article (PubMed ID: 17585539)
21. Are intracystic chromogranin A and neuron-specific enolase useful in the diagnosis of cystic pancreatic neuroendocrine tumors?
Varas Lorenzo MJ; Llebaria Puig C
Rev Esp Enferm Dig; 2024 Jan; ():. PubMed ID: 38205719
[TBL] [Abstract][Full Text] [Related]
22. Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift.
Waldum HL; Öberg K; Sørdal ØF; Sandvik AK; Gustafsson BI; Mjønes P; Fossmark R
Therap Adv Gastroenterol; 2018; 11():1756284818775054. PubMed ID: 29872453
[TBL] [Abstract][Full Text] [Related]
23. Correction to Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumours and differentiation from small intestinal neuroendocrine tumours. J Neuroendocrinol. 2022 Jul;34(7):e13176.
J Neuroendocrinol; 2024 Mar; 36(3):e13368. PubMed ID: 38287535
[No Abstract] [Full Text] [Related]
24. Composite haemangioendothelioma with neuroendocrine marker differentiation presenting as a pink-brown nodule.
Jones CME; Nieweg OE; Isaacs F; Cheung K
Australas J Dermatol; 2024 Mar; 65(2):174-177. PubMed ID: 38095137
[TBL] [Abstract][Full Text] [Related]
25. S100 protein is commonly expressed in neuroendocrine tumours of major and minor ampulla.
Vanoli A; Inzani F; Parente P; Albarello L; Fassan M; Grillo F; Messina A; Carlino A; Uccella S; Spaggiari P; La Rosa S; Rindi G
J Clin Pathol; 2024 Jun; ():. PubMed ID: 38849197
[No Abstract] [Full Text] [Related]
26. A Missing Link between Neuron Specific Enolase Release and Poor Prognosis in Aging Patients with B-cell Lymphoma.
Polcyn R; God J; Capone M; Matzelle D; Banik NL; Haque A
J Clin Cell Immunol; 2018; 9(3):. PubMed ID: 30464859
[No Abstract] [Full Text] [Related]
27. Exploring the molecular and biological background of lung neuroendocrine tumours.
Simbolo M; Di Noia V; D'Argento E; Milella M; Scarpa A; Tortora G; Bria E; Pilotto S
J Thorac Dis; 2019 May; 11(Suppl 9):S1194-S1198. PubMed ID: 31245083
[No Abstract] [Full Text] [Related]
28. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
29. Chromogranin A, neuron-specific enolase and synaptophysin as neuroendocrine cell markers in the diagnosis of tumours of the gastro-entero-pancreatic system.
Schürmann G; Betzler M; Buhr HJ
Eur J Surg Oncol; 1990 Aug; 16(4):298-303. PubMed ID: 2116326
[TBL] [Abstract][Full Text] [Related]
30. A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines.
Jensen SM; Gazdar AF; Cuttitta F; Russell EK; Linnoila RI
Cancer Res; 1990 Sep; 50(18):6068-74. PubMed ID: 2168288
[TBL] [Abstract][Full Text] [Related]
31. Effect of BANS location on the prognosis of clinical stage I melanoma: new data and meta-analysis.
Weinstock MA; Morris BT; Lederman JS; Bleicher P; Fitzpatrick TB; Sober AJ
Br J Dermatol; 1988 Nov; 119(5):559-65. PubMed ID: 3207610
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of synaptophysin and chromogranin a expression in patients receiving palliative chemotherapy for advanced non-small-cell lung cancer.
Kowalski DM; Krzakowski M; Jaśkiewicz P; Olszewski W; Janowicz-Żebrowska A; Wojas-Krawczyk K; Krawczyk P
Respiration; 2013; 85(4):289-96. PubMed ID: 22472871
[TBL] [Abstract][Full Text] [Related]
33. Synaptophysin and neurofilament proteins as markers for neuroendocrine tumors.
Miettinen M
Arch Pathol Lab Med; 1987 Sep; 111(9):813-8. PubMed ID: 2820344
[TBL] [Abstract][Full Text] [Related]
34. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects.
Isgrò MA; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():125-43. PubMed ID: 26530364
[TBL] [Abstract][Full Text] [Related]
35. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
36. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
37. NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy.
Li J; Zhang H; Xie M; Yan L; Chen J; Wang H
Diabetes Care; 2013 Nov; 36(11):3405-10. PubMed ID: 23846809
[TBL] [Abstract][Full Text] [Related]
38. [Chromogranin A and neuroendocrine tumors].
Díaz Pérez JÁ; Currás Freixes M
Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
[TBL] [Abstract][Full Text] [Related]
39. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
[TBL] [Abstract][Full Text] [Related]
40. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
